182 related articles for article (PubMed ID: 26059265)
21. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
[TBL] [Abstract][Full Text] [Related]
23. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
24. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
[TBL] [Abstract][Full Text] [Related]
26. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
28. Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.
Sandström K; Haylock AK; Velikyan I; Spiegelberg D; Kareem H; Tolmachev V; Lundqvist H; Nestor M
Cancer Biother Radiopharm; 2011 Oct; 26(5):593-601. PubMed ID: 21834651
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277
[TBL] [Abstract][Full Text] [Related]
30. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
31. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
32. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.
Tolmachev V; Hofström C; Malmberg J; Ahlgren S; Hosseinimehr SJ; Sandström M; Abrahmsén L; Orlova A; Gräslund T
Bioconjug Chem; 2010 Nov; 21(11):2013-22. PubMed ID: 20964447
[TBL] [Abstract][Full Text] [Related]
33. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
[TBL] [Abstract][Full Text] [Related]
35. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
[TBL] [Abstract][Full Text] [Related]
36. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
37. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
[TBL] [Abstract][Full Text] [Related]
38. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
[TBL] [Abstract][Full Text] [Related]
39. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
[TBL] [Abstract][Full Text] [Related]
40. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]